The Israeli Ministry of Health (MoH) has granted marketing approval for Vanda Pharmaceuticals' Fanapt for the treatment of schizophrenia.
Vanda will commercialize Fanapt in Israel through its partner Megapharm Ltd., a leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel.
Fanapt tablets are indicated for the treatment of adults with schizophrenia.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.